Giuseppe Viale
机构: Università di Milano e Istituto Europeo di Oncologia
每年引用次数
引用次数
引用: 137,473
H-指数: 166
I10-指数 : 750
出版物: 1,523
Abstract P4-08-05: Impact of common polymorphisms of CYP19A1 and UGT2B17 gene deletion on early endocrine-responsive postmenopausal breast cancer
H Johansson , S Gandini , V Aristarco , D Macis
Cancer Research 78
2018
Abstract P4-15-06: Low dose tamoxifen lowers recurrences after mastectomy for in situ neoplasia. Ten-year results of a monoinstitutional study
A Guerrieri-Gonzaga , S Gandini , D Serrano , M Lazzeroni
Cancer Research 78
2018
Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer.
G Pelosi , U Pastorino , F Pasini , P Maissoneuve
British Journal of Cancer 88 ( 4) 537 -547
153
2003
Distribution of tenascin in human malignant gliomas is not related to cell proliferation.
P Castellani , A Siri , L Zardi , A Barbanera
Journal of Neurology, Neurosurgery, and Psychiatry 62 ( 3) 290 -291
5
1997
Immunohistochemical localization of human immunoglobulins and lysozyme in epoxy-embedded lymph nodes: effect of different fixatives and of proteolytic digestion.
P Dell'Orto , G Viale , R Colombi , P Braidotti
Journal of Histochemistry and Cytochemistry 30 ( 7) 630 -636
22
1982
Ultrastructural localization of intracellular immunoglobulins in Epon-embedded human lymph nodes. An immunoelectron microscopic investigation using the immunogold staining (IGS) and the avidin-biotin-peroxidase complex (ABC) methods.
G Viale , P Dell'Orto , P Braidotti , G Coggi
Journal of Histochemistry and Cytochemistry 33 ( 5) 400 -406
23
1985
Prediction of response to primary chemotherapy for operable breast cancer
M Colleoni , E Orvieto , F Nolé , L Orlando
European Journal of Cancer 35 ( 4) 574 -579
101
1999
Abstract P1-01-01: Analytical validation of a standardized scoring protocol for Ki67: Phase-3 of an international multicenter collaboration
M Dowsett , SCY Leung , L Zabaglo , I Arun
Cancer Research 76
9
2016
Abstract P1-01-16: Performance evaluation of two ready-to-use antibodies under development for the Dako Omnis automated staining platform on breast carcinoma specimens: Anti-estrogen receptor α clone EP1 and anti-progesterone receptor clone PgR 1294
G Viale , P Dell'Orto , M Falzon , A Fält
Cancer Research 76
2016
Abstract P1-05-01: The epithelial to mesenchymal transition: Identifying a signature of recurrence in ductal carcinoma in situ
J Felipe Lima , CQ Yao , F Yan , D Dion
Cancer Research 76
2016
Abstract P4-21-41: Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer
SM Swain , MS Ewer , G Viale , S Delaloge
Cancer Research 77
3
2017
Abstract P4-21-39: Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo study
L Gianni , G Bisagni , M Colleoni , L Del Mastro
Cancer Research 77
5
2017
Abstract P5-14-01: Chemotherapy randomization of the EORTC 10041/ BIG 3-04 MINDACT (microarray in node-negative and 1 to 3 positive lymph node disease may avoid chemotherapy) trial
F Cardoso , M Piccart , E Rutgers , L Slaets
Cancer Research 77
2017
Abstract P2-08-02: Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple negative breast cancer treated by induction chemotherapy with or without oral low dose cyclophosphamide-methotrexate maintenance chemotherapy (CMM)
I Láng , B Thürlimann , A Goldhirsch , KN Price
Cancer Research 76
1
2016
Abstract P3-07-36: Immune related gene expression signatures predict benefit of letrozole over tamoxifen in BIG 1-98
S Willis , KP Gray , MM Regan , JM Rae
Cancer Research 76
2016
Abstract P5-07-02: Systematic analysis and modulation of Ki67 interobserver variance in 9069 patients from three clinical trials – How much pathologist concordance is needed for meaningful biomarker results?
C Denkert , J Budczies , M Regan , S Loibl
Cancer Research 76
2016
Abstract S1-02: Lymphocytic infiltration in invasive lobular breast cancer
C Desmedt , R Salgado , L Buisseret , G Zoppoli
Cancer Research 76
1
2016
Abstract S4-06: HER2 status as predictive marker for AI vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
JMS Bartlett , I Ahmed , MM Regan , I Sestak
Cancer Research 76
2016
Abstract PD7-01: Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial
F Cardoso , L Slaets , F de Snoo , J Bogaerts
Cancer Research 77
2
2017
Abstract S1-10: Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study
S Loi , R Asher , CK Lee , S Luen
Cancer Research 77
2
2017